1. Home
  2. ETR vs UTHR Comparison

ETR vs UTHR Comparison

Compare ETR & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Entergy Corporation

ETR

Entergy Corporation

HOLD

Current Price

$92.15

Market Cap

42.2B

Sector

Utilities

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$493.41

Market Cap

20.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ETR
UTHR
Founded
1949
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
42.2B
20.3B
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
ETR
UTHR
Price
$92.15
$493.41
Analyst Decision
Buy
Buy
Analyst Count
17
12
Target Price
$100.44
$495.08
AVG Volume (30 Days)
2.8M
411.6K
Earning Date
10-29-2025
10-29-2025
Dividend Yield
2.77%
N/A
EPS Growth
N/A
16.08
EPS
4.07
26.38
Revenue
$12,730,047,000.00
$3,128,400,000.00
Revenue This Year
$9.16
$13.64
Revenue Next Year
$7.39
$5.78
P/E Ratio
$22.70
$18.73
Revenue Growth
7.32
13.50
52 Week Low
$73.15
$266.98
52 Week High
$98.58
$496.73

Technical Indicators

Market Signals
Indicator
ETR
UTHR
Relative Strength Index (RSI) 38.81 65.89
Support Level $92.21 $474.59
Resistance Level $93.86 $489.99
Average True Range (ATR) 1.63 10.16
MACD -0.26 -0.69
Stochastic Oscillator 6.88 91.64

Price Performance

Historical Comparison
ETR
UTHR

About ETR Entergy Corporation

Entergy is a holding company with five regulated vertically integrated utilities that generate and distribute electricity to 3 million customers in Arkansas, Louisiana, Mississippi, and Texas. It is one of the largest power producers in the country with 27 gigawatts of rate-regulated owned and leased power generation capacity. Entergy was the second-largest nuclear owner in the US before it began retiring and selling its plants in the Northeast in 2014. It sold its two small gas utilities in Louisiana in 2025.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: